Welcome to our dedicated page for Vicarious Surgical SEC filings (Ticker: RBOT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading Vicarious Surgical’s SEC paperwork often means decoding pages of robotics engineering details, FDA trial data, and prototype cost breakdowns. If you have ever searched for “Vicarious Surgical SEC filings explained simply” or wondered how executive stock sales line up with regulatory milestones, you know the challenge.
Stock Titan solves that complexity. Our AI instantly scans every new document from the company’s real-time EDGAR feed—whether it’s a Vicarious Surgical quarterly earnings report 10-Q filing or a sudden Vicarious Surgical 8-K material events explained alert—and delivers plain-language summaries, trend charts, and red-flag highlights. You will see cash-burn trends, R&D outlays, and single-port robotics development updates without wading through technical jargon.
Here is what investors monitor most—and how our platform helps:
- 10-K / Annual insight: Get the Vicarious Surgical annual report 10-K simplified so you can track FDA pathway progress and component sourcing risks.
- 10-Q / Quarterly performance: Compare revenue runway and prototype expenses with our Vicarious Surgical earnings report filing analysis.
- Form 4 insider alerts: Follow Vicarious Surgical insider trading Form 4 transactions and receive Vicarious Surgical Form 4 insider transactions real-time push notices.
- Proxy statement: Drill into Vicarious Surgical proxy statement executive compensation to see how bonuses hinge on FDA milestones.
Need deeper context? Try understanding Vicarious Surgical SEC documents with AI—our narrative commentary ties robotic-arm dexterity claims to actual spending, while clear call-outs show Vicarious Surgical executive stock transactions Form 4 right next to board meeting dates. From early-morning 8-K announcements to late-day amendment filings, every disclosure appears on this page within minutes, already distilled into the insights that matter.
Vicarious Surgical Inc. (RBOT) filing a Form 144 notifies proposed sale of 40,427 shares of Class A common stock through two brokers for planned sale on 09/22/2025. The shares break down as 32,469 with Interactive Brokers (aggregate market value $189,943.65) and 7,958 with UBS Financial Services (aggregate market value $46,554.30), against 5,298,253 shares outstanding. The reporting person acquired a total of 45,339 shares over multiple dates via distributions and vesting from 2021–2024. In the prior three months the filer sold 4,912 shares for gross proceeds of $31,540.00. The signer certifies no undisclosed material adverse information.
Adam David Sachs, a director, 10% owner and President of Vicarious Surgical Inc. (RBOT), reported a non-discretionary sale on 09/03/2025 of 463 shares of Class A common stock to satisfy tax-withholding obligations from restricted stock units granted on June 2, 2023. The transactions were executed as a "sell-to-cover" under the companys equity plan at a weighted average price of $5.7564 per share (trades ranged from $5.64 to $5.87). After the sale, the reporting person beneficially owned 49,164 shares directly. The Form 4 was submitted by an attorney-in-fact on 09/04/2025.
Vicarious Surgical Inc. (RBOT) Form 4: insider sale to cover taxes
Khalifa Sammy, listed as Chief Technology Officer, Director and a 10% owner, reported a sale of 239 shares of Class A common stock on 09/03/2025 at a weighted average price of $5.7195 per share. The filing states the sale was a mandatory "sell to cover" to satisfy tax withholding on restricted stock units granted June 2, 2023, and therefore was not a discretionary trade. After the transaction, the reporting person beneficially owned 34,515 shares. The filer signed via attorney-in-fact on 09/04/2025.
Form 144 filed for Vicarious Surgical Inc. (RBOT) discloses a proposed sale of 463 shares of Class A common stock through UBS Financial Services on 09/03/2025 with an aggregate market value of $2,685. The filing states the shares were acquired by restricted stock lapse on 09/02/2025 and lists total shares outstanding as 5,298,253. The notice also reports three prior sales by the same person during the past three months totaling 1,559 shares with aggregate gross proceeds of $10,040. The filer affirms no undisclosed material adverse information and includes standard signature and legal attestations.
Vicarious Surgical Inc. (RBOT) Form 144 shows a proposed sale of 239 shares of Class A common stock through UBS Financial Services with an aggregate market value of $1,386 and an approximate sale date of 09/03/2025 on the NYSE. The filing reports the securities were acquired on 09/02/2025 via a restricted stock lapse from Vicarious Surgical Inc. and indicates 696 shares were acquired in that transaction.
The filing also discloses three prior sales by the listed seller, Sammy Khalifa, during the past three months: 239 shares on 06/03/2025 for $1,641, 223 shares on 06/23/2025 for $1,650, and 653 shares on 08/20/2025 for $3,801. The notice includes the standard signature representation that the seller is not aware of undisclosed material adverse information about the issuer.
Donald F. Tang, a director of Vicarious Surgical Inc. (RBOT), reported an open-market sale of 2,753 shares of Class A common stock on 08/26/2025 at a weighted average price of $6.6965 per share. Following the sale, the filing shows Mr. Tang beneficially owned 40,425 shares. The Form 4 was executed by an attorney-in-fact on 08/27/2025. The filing discloses the weighted average price represents multiple trades that ranged from $6.64 to $7.15 per share, and the reporting person offers to provide trade-specific quantities and prices to SEC staff or the company on request.
FAQ
What is the current stock price of Vicarious Surgical (RBOT)?
What is the market cap of Vicarious Surgical (RBOT)?
